The Pritzker School of Molecular Engineering, Cummings Life Science Center, The University of Chicago , Chicago, IL, USA.
The Ben May Department for Cancer Research, Cummings Life Science Center, The University of Chicago , Chicago, IL, USA.
J Exp Med. 2025 Jan 6;222(1). doi: 10.1084/jem.20241581. Epub 2024 Nov 25.
In this issue of JEM, Robles-Oteiza et al. (https://doi.org/10.1084/jem.20231106) present compelling evidence linking tumor hypoxia to acquired resistance mechanisms in non-small cell lung cancer (NSCLC) treatments involving immune checkpoint inhibitors (ICIs). Their research advocates targeting these hypoxic tumor regions with hypoxia-activated pro-drugs like TH-302, which may substantially delay the onset of resistance and herald a significant advancement in cancer therapy.
在本期《实验医学杂志》中，Robles-Oteiza 等人（https://doi.org/10.1084/jem.20231106）提出了令人信服的证据，将肿瘤缺氧与涉及免疫检查点抑制剂（ICI）的非小细胞肺癌（NSCLC）治疗中获得性耐药机制联系起来。他们的研究主张用缺氧激活前药（如 TH-302）靶向这些缺氧肿瘤区域，这可能会大大延迟耐药的发生，并为癌症治疗带来重大进展。
